scholarly journals METHYLENE BLUE IN REFRACTORY SEPTIC SHOCK

CHEST Journal ◽  
2020 ◽  
Vol 158 (4) ◽  
pp. A2558
Author(s):  
Mouhanned Eliliwi ◽  
Jennifer Meyfeldt ◽  
Stephanie Hart ◽  
Eliot Friedman
2016 ◽  
Vol 44 (12) ◽  
pp. 573-573
Author(s):  
Cyril Varghese ◽  
Erin Demartino ◽  
Egan Ashley ◽  
Jaclyn Jacobi ◽  
Daniels Lisa ◽  
...  

2021 ◽  
Vol 18 (3) ◽  
pp. 79-86
Author(s):  
L. L. Plotkin

Refractory shock is the shock that does not respond to vasopressor therapy. Refractory shock with a short-term mortality rate of more than 50% is diagnosed in 6-7% of critically ill patients. There is an objective need to Investigate methods of intensive therapy for refractory septic shock.The objective of the study: to analyze literature data on the intensive care of refractory septic shock.Results. The second part of the article analyzes 37 studies, both Russian and foreign ones devoted to the intensive care of refractory shock. At present, based on the analysis of the publication, it is impossible to draw reasonable conclusions about the advantage of one or another method of intensive therapy for refractory shock (veno-venous hemofiltration, the use of angiotensin II and vasopressin, as well as methylene blue, vitamin B12, ECMO) over basic therapy.


2005 ◽  
Vol 20 (2) ◽  
pp. 123 ◽  
Author(s):  
Byung-Kyu Park ◽  
Tae-Sun Shim ◽  
Chae-Man Lim ◽  
Sang-Do Lee ◽  
Woo-Sung Kim ◽  
...  

2011 ◽  
Vol 58 (4) ◽  
pp. 401-405 ◽  
Author(s):  
Tristan C. Dumbarton ◽  
Samuel Minor ◽  
Colin K. Yeung ◽  
Robert Green

Author(s):  
R. Ismail ◽  
H. Awad ◽  
R. Allam ◽  
O. Youssef ◽  
M. Ibrahim ◽  
...  

BACKGROUND: Refractory septic shock in neonates is still associated with high mortality, necessitating an alternative therapy, despite all currently available treatments. This study aims to assess the vasopressor effect of methylene blue (MB) in comparison to terlipressin (TP) as adjuvant therapy for refractory septic shock in the preterm neonate. METHODS: A double-blinded randomized controlled trial was conducted in the Neonatal Intensive Care Units at Ain Shams University, Egypt. Thirty preterm neonates with refractory septic shock were randomized to receive either MB or TP as an adjuvant to conventional therapy. Both MB and TP were administered as an intravenous loading dose followed by continuous intravenous infusion. The hemodynamic variables, functional echocardiographic variables, and oxidant stress marker were assessed over a 24 h period together with the side effects of MB. RESULTS: MB causes significant improvement in mean arterial blood pressure with a significant decrease of the norepinephrine requirements (1.15±0.21μm/kg/min at baseline vs. 0.55±0.15μm/kg/min at 24 h). MB infusion causes an increase of the pulmonary pressure (44.73±8.53 mmHg at baseline vs. 47.27±7.91 mmHg after 24 h) without affecting the cardiac output. Serum malonaldehyde decreased from 5.45±1.30 nmol/mL at baseline to 4.40±0.90 nmol/mL at 24 h in the MB group. CONCLUSION: Administration of MB to preterm infants with refractory septic shock showed rapid increases in systemic vascular resistance and arterial blood pressure with minimal side effects.


2020 ◽  

Introduction: Methylene blue is receiving special interest in perioperative and intensive care of patients with distributive shock due to its ability to block the action of nitric oxide and to antagonize deep vasodilation. Objective: The objective is to illustrate the use of the methylene blue, summarizing the perioperative management of a case with secondary vasoplegic syndrome due to a norepinephrine refractory septic shock and the response to methylene blue, reviewing the latest evidence of this therapeutic alternative. In practice:We describe the case of a 60-year-old man, paraplegic, with septic shock due to a long evolution decubitus pressure ulcer. After two hours of surgery, the patient remained with hemodynamic deterioration despite high doses of vasopressin (3 IU/hour) and norepinephrine (2 µg/kg /min), therefore methylene blue was administered with two intravenous bolus doses of 50 mg without adverse effects. After half an hour hemodynamic improvement was evidenced, allowing to decrease norepinephrine infusion and normalizing blood pressure. Finally, debridement of necrotic tissue, amputation and disarticulation of left coxofemoral joint was performed with subsequent transfer to the ICU and discharge to the spinal cord injury ward twenty eight days later. Conclusions: As it has been demonstrated in our patient, methylene blue is a therapeutic alternative to manage patients with persistent hypotension despite the use of various vasopressors during the management of vasoplegic syndrome secondary to septic shock.


Critical Care ◽  
10.1186/cc68 ◽  
1997 ◽  
Vol 1 (Suppl 1) ◽  
pp. P076
Author(s):  
M Andresen ◽  
A Dougnac ◽  
M Alvarez ◽  
G Hernandez ◽  
O Diaz ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document